eXmoor Pharma managing director Angela Osborne has been named in BioBeat’s “50 Movers and Shakers” which lists the most influential women in UK healthcare businesses.
Ms. Osborne founded the biopharmaceutical and cell therapy manufacturing consultancy eXmoor Pharma in 2004 and has since grown it into a globally recognized leader in its field that has completed more than 300 projects across 12 countries.
In September 2010 she co-founded the Advanced Therapy Medicinal Products (ATMP) Manufacturing Community, or amc, to build critical mass and facilitate the sharing of expertise in ATMP manufacturing. The amc now boasts 170 fee paying members.
Ms. Osborne is a member of the BioIndustry Association (BIA)’s Cell Therapy Industry Group and Manufacturing Groups’ advisory committees. She has now been named alongside 49 other “outstanding” female healthcare business leaders in the 2018 BioBeat list which aims to emphasise the role of women leading and innovating to ensure new technologies and treatments continue to improve UK research, health and society.
Ms, Osborne commented: “There is amazing work being done by women across the board developing new products and processes and pushing the boundaries of bioscience in ways that will hopefully benefit everyone in years to come.
“My inclusion on this list is really thanks to the hard work and dedication of all our talented team at eXmoor who between them have more than 300 years’ combined experience in gene and cell therapy and biopharmaceuticals.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.